№ files_lp_4_process_2_55586
File format: docx Character count: 1658 File size: 27 KB
Clinical recommendation letter from a respiratory specialist to a general practitioner outlining initiation and monitoring of azithromycin therapy for patients with COPD or bronchiectasis experiencing exacerbations.
Document type: Clinical correspondence letter
Medical topic: COPD and bronchiectasis management
Medication: Azithromycin
Purpose: Recommendation to initiate azithromycin therapy to reduce exacerbations
Sender role: Respiratory specialist
Recipient role: General Practitioner
Patient category: Patients with COPD or bronchiectasis experiencing exacerbations
Clinical objective: Reduction in number of exacerbations within a 12-month period
Review schedule: 6 months after treatment initiation and additional follow-up months as specified
Prescribing status: Amber Recommended
Prescribing guidance source: Pan-Mersey Area Prescribing Committee
Response requirement: GP confirmation or refusal within 14 days
Sections included: Treatment dose and frequency, indication, review plan, GP decision section
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Patient Group Direction for the supply of azithromycin for the prevention of diphtheria in high risk settings or during outbreaks, version 02.00, valid from 21 November 2022 to 20 November 2024
Year: 2022
Region / country: United Kingdom
Topic: Public health; infectious disease prevention
Document type: Patient Group Direction (PGD)
Organization: UK Health Security Agency (UKHSA)
Authors: Jacqueline Lamberty, Mary Ramsay, Kate Wedgwood
Target audience: Registered healthcare practitioners
Valid from: 21 November 2022
Review date: 21 May 2024
Expiry date: 20 November 2024
Version: 02.00
Changes history: Removal of Sandoz as exclusive brand, addition of off-label use for Pfizer suspension, guidance for suspension handling
Authorization requirements: Named practitioner authorization under current PGD version, organizational sign-off according to HMR2012
Training requirements: Competency in PGDs, product familiarity, local policy training compliance
Source type: Regulatory/healthcare guidance document
PGD development: Peer-reviewed by expert panel and ratified by UKHSA Clinical Quality Oversight Board
Topics: Exacerbations Bronchiectasis azithromycin